HeartWare International (NSDQ:HTWR) is looking to get in on Dr. Stephen Oesterle, an Ex-Medtronic (NYSE:MDT) exec who moved to the venture capital firm New Enterprise Associates last Sept., saying this week that it expanded its board to accommodate Oesterle. Oesterle will officially come aboard on Jan. 18, and his appointment included an expansion to HeartWare’s board […]
HeartWare International Inc.
HeartWare plunges on uncertainty around its next-gen MVAD pump
Shares of HeartWare International (NSDQ:HTWR) are down some 28% today after the implantable heart pump maker said it can’t predict when it will be able to get its next-generation MVAD program back on line. Framingham, Mass.-based HeartWare said it expects to post sales of roughly $68 million for the 3 months ended Dec. 31, in line […]
Medtronic CEO Ishrak unfazed by Google’s medtech endeavors
With more large consumer tech firms like Apple (NSDQ:AAPL) dabbling in medtech and Google (NSDQ:GOOG) fully entering into the medical device arena, the field is getting more competitive – but Medtronic CEO Omar Ishrak isn’t intimidated. What Medtronic’s CEO sees in Google is less an opportunity for a new competitor, and more a chance for future […]
HeartWare shareholder threatens proxy fight over Valtech merger
HeartWare International (NSDQ:HTWR) may face a proxy battle from a shareholder over its proposed acquisition of Israeli replacement heart valve maker Valtech Cardio, according to an SEC filing posted yesterday. The company said it received a notice from shareholding firm Engaged Capital nominating 3 board members and opposing its proposed acquisition of Valtech. “While we […]
Report: TMVR at least 4 years from U.S. market
Transcatheter mitral valve replacements are at least 4 years out from hitting the U.S. market, despite the $2 billion recently dropped on companies developing the technology by some of the top names in medtech. Medtronic (NYSE:MDT), Abbott (NYSE:ABT), Edwards Lifesciences (NYSE:EW) and HeartWare International (NSDQ:HTWR) in recent months have spent a total of $2 billion to buy […]
HeartWare clears final anti-trust hurdle on Valtech Cardio buy
HeartWare International (NSDQ:HTWR) said today that it’s past the waiting period required to satisfy U.S. anti-trust regulations for its pending acquisition of Israeli replacement heart valve maker Valtech Cardio. That marks the final anti-trust hurdle for the deal, which must still be approved by the companies’ shareholders. HTWR shares, off -44% since the deal’s Sept. 1 announcement, rose […]
HeartWare looks to get MVAD program back on track
HeartWare International (NSDQ:HTWR) said today that it’s on track to restart a CE Mark trial for its MVAD implantable heart pump. Investors initially pared 30.0% from HTWR shares after the company said Oct. 12 that it might not be able to resume the trial as soon as was expected. Framingham, Mass.-based HeartWare, which put a hold on enrollment in its CE […]
HeartWare plunges on extended pause for MVAD trial
Investors have pared 30.0% from HeartWare International (NSDQ:HTWR) since the company said yesterday that it may not be able to resume a trial of its MVAD implantable heart pump next month, as was expected. Framingham, Mass.-based HeartWare, which put a hold on enrollment in its CE Mark trial Sept. 9 due to controller manufacturing and software issues, said […]
Activist investor fights HeartWare’s $766m Valtech buy
Activist investor Engaged Capital, a recent backer of HeartWare International (NSDQ:HTWR), is trying to block the implantable heart pump maker’s $766 million buyout of Valtech Cardio. The deal for Valtech calls for an up-front payment of 4.4 million shares of HeartWare stock, plus potential milestones of 800,000 shares when Valtech’s Cardioband annuloplasty device wins CE Mark approval in […]
Valtech Cardio wins CE Mark for Cardioband mitral repair device
Valtech Cardio, which agreed to be acquired by HeartWare International (NSDQ:HTWR) earlier this month, today said it won CE Mark approval in the European Union for its Cardioband mitral valve repair device. Or Yehuda, Israel-based Valtech said it plans to unveil the Cardioband device at the PCR London Valves meeting in Berlin next week. “We are […]
HeartWare pauses MVAD trial
UPDATED Sept. 10, 2015, with details on MVAD trial pause, expanded field action and Valtech acquisition. HeartWare International (NSDQ:HTWR) today said it’s pausing enrollment in a clinical trial of its next-generation MVAD heart pump while it looks to fix an issue with the manufacturing process for the left ventricular assist device’s controller. Framingham, Mass.-based HeartWare said […]